-Company to announce third quarter financial results on Thursday, November 1, 2012-
Press Release: Vertex Pharmaceuticals Incorporated – Mon, Oct 29, 2012 9:11 AM EDT.. .
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
As a result of the effects of Hurricane Sandy and the related closure of the financial markets, Vertex Pharmaceuticals Incorporated (VRTX) today announced that it has rescheduled its third quarter 2012 earnings press release and conference call, which were originally scheduled for today, Monday, October 29. Vertex will now announce its third quarter 2012 financial results on Thursday, November 1, 2012 after the financial markets close. The company will host a conference call at 5:00 p.m. EDT on Thursday.
The conference call will be webcast live and a link to the webcast may be accessed from the ‘Events & Presentations' page of Vertex's website at www.vrtx.com. A replay of the conference call and webcast will be archived on the company's website until November 15, 2012. To ensure a timely connection, it is recommended that users register at least 15 minutes prior to the scheduled webcast.
About Vertex
Vertex creates new possibilities in medicine. Our team discovers, develops and commercializes innovative therapies so people with serious diseases can lead better lives.
Vertex scientists and our collaborators are working on new medicines to cure or significantly advance the treatment of hepatitis C, cystic fibrosis, rheumatoid arthritis and other life-threatening diseases.
Founded more than 20 years ago in Cambridge, Mass., we now have ongoing worldwide research programs and sites in the U.S., U.K. and Canada. Today, Vertex has more than 2,000 employees around the world, and for three years in a row, Science magazine has named Vertex one of its Top Employers in the life sciences. Vertex's press releases are available at www.vrtx.com.
VRTX – GEN
Recent VRTX News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/04/2024 08:13:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/04/2024 08:12:39 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/30/2024 08:47:28 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/30/2024 08:23:37 PM
- Vertex to Participate in Upcoming September Investor Conferences • Business Wire • 08/22/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/16/2024 08:04:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/12/2024 08:08:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/08/2024 08:06:24 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/08/2024 03:47:17 PM
- Vertex Announces CASGEVY™ Reimbursement Agreement for the Treatment of Transfusion-Dependent Beta Thalassemia in England • Business Wire • 08/07/2024 11:12:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/07/2024 01:52:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/02/2024 08:10:07 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/02/2024 08:03:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 08:17:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2024 08:05:43 PM
- Vertex Reports Second Quarter 2024 Financial Results • Business Wire • 08/01/2024 08:01:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/01/2024 07:34:43 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/30/2024 07:25:57 PM
- Vertex Announces FDA Acceptance of New Drug Application for Suzetrigine for the Treatment of Moderate-to-Severe Acute Pain • Business Wire • 07/30/2024 05:10:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/25/2024 08:06:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/24/2024 08:05:44 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/24/2024 04:27:07 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/22/2024 05:16:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 08:13:27 PM
- Santé Canada autorise la commercialisation de TRIKAFTA(MD) (éléxacaftor/tézacaftor/ivacaftor et ivacaftor) chez les personnes atteintes de fibrose kystique âgées de 2 ans et plus présentant certaines mutations rares • PR Newswire (Canada) • 07/15/2024 01:00:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM